Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:56:40 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



Q:LPTX - LEAP THERAPEUTICS INC - https://www.leaptx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LPTX - Q0.62.57·2.770.12.63-0.11-4.0377.29211,1632.77  2.77  2.5710.20  1.23518:59:28May 1315 min RT 2¢

Recent Trades - Last 10 of 1163
Time ETExPriceChangeVolume
18:59:28Q2.70-0.041,000
17:47:08Q2.6048-0.135221
17:47:08Q2.60-0.1421
17:17:17Q2.60-0.14400
16:00:07Q2.675-0.0651
16:00:01Q2.63-0.11397
16:00:01Q2.63-0.11100
16:00:01Q2.63-0.1122
16:00:01Q2.63-0.11100
16:00:01Q2.63-0.1191

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-13 07:00U:LPTXNews ReleaseLeap Therapeutics Reports First Quarter 2024 Financial Results
2024-04-11 08:30U:LPTXNews ReleaseLeap Therapeutics Announces $40 Million Private Placement
2024-03-18 07:00U:LPTXNews ReleaseLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
2024-01-16 17:05U:LPTXNews ReleaseLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
2024-01-03 07:00U:LPTXNews ReleaseLeap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 07:00U:LPTXNews ReleaseLeap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
2023-12-11 16:05U:LPTXNews ReleaseLeap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
2023-11-21 07:00U:LPTXNews ReleaseLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
2023-11-13 07:00U:LPTXNews ReleaseLeap Therapeutics Reports Third Quarter 2023 Financial Results
2023-09-05 07:00U:LPTXNews ReleaseLeap Therapeutics to Participate at Upcoming Investor Conferences
2023-08-14 07:00U:LPTXNews ReleaseLeap Therapeutics Reports Second Quarter 2023 Financial Results
2023-07-12 07:00U:LPTXNews ReleaseLeap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
2023-06-20 12:30U:LPTXNews ReleaseLeap Therapeutics Announces Reverse Stock Split
2023-05-25 17:10U:LPTXNews ReleaseLeap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting